Clinical Trial Update: A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants [Phase 1]

View source ↗

Summary

A dose-escalation Phase 1 trial of HXN5003 in healthy participants is not yet recruiting, sponsored by Helixon Biotechnology (Suzhou) Co., Ltd. The listed condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• HXN5003

Snippet

Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd | Conditions: Atopic Dermatitis | Phase 1 | Status: NOT_YET_RECRUITING